ArticleEye (London, England)2025
Baseline factors that are associated with change in visual acuity in intermediate AMD over two years in a multicentre cohort study in Europe- INTERCEPT-AMD Report 2.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND/
objectivesThe aim of this study was to evaluate the change in visual acuity (VA) in participants with intermediate age-related macular degeneration (iAMD) over two years when categorised by the presence or absence of incomplete retinal and retinal pigment atrophy (iRORA) and subretinal drusenoid deposits (SDD). SUBJECTS/
methodsIn this multicentre cohort study, participants with iAMD were classified as: i) iAMD with no iRORA or SDD; ii) iAMD with SDD with no iRORA; iii) iAMD with iRORA with no SDD and iv) iAMD with iRORA and SDD. The change in best recorded visual acuity (BRVA) over two years in the whole cohort and in each sub-category was analysed using linear mixed effect models employing an unstructured covariance structure. Associations with age, sex and baseline BRVA were evaluated.
results983 eyes from 805 participants were analysed. The mean baseline VA changed from 79.8 (SD 8.1) to 77.7 (SD 10.1) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at two years, with a mean unadjusted change in BRVA of -0.33 ETDRS letters (95% CI -0.72,0.06); P = 0.10 at 6 months, -0.65 ETDRS letters (95% CI -1.14, -0.16); P = 0.01 at 12 months, -1.45 ETDRS letters (95% CI -2.03, -0.86); P < .001 at 18 months and -2.16 ETDRS letters (95% CI -2.79, -1.53); P < .001 at 24 months. All sub-categories showed a small decline in BRVA. Increasing age and lower baseline visual acuity were associated with lower BRVA over two years.
conclusionEyes with iAMD experience a small mean decline of ~2 letters over two years. Overall, these changes may not represent a clinically meaningful difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.